Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
91.62 EUR | +4.47% | +7.50% | +2.07% |
05:31pm | CAC40: losses trimmed, rates remain at their zenith | CF |
05:11pm | European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.07% | 117B | B+ | ||
+24.17% | 562B | B | ||
-6.27% | 358B | C+ | ||
+18.72% | 322B | B- | ||
+7.50% | 297B | C+ | ||
+13.53% | 219B | B+ | ||
+6.06% | 199B | B- | ||
-10.35% | 196B | A+ | ||
-11.13% | 149B | C+ | ||
-6.78% | 146B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SAN Stock
- Ratings Sanofi